NCT01285102终止1 期
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Time to Progression
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Chemoembolization kills tumor cells by blocking blood flow to the tumor and keeping chemotherapy drugs near the tumor.
PURPOSE: This phase II trial is studying how well chemoembolization using irinotecan works in treating patients with liver metastases from metastatic colon or rectal cancer.
详细描述
PRIMARY OBJECTIVES:
I. To define the response rate of colorectal liver metastases (in the treated lobe) treated with DEBIRI, in refractory mCRC patients.
SECONDARY OBJECTIVES:
I. To evaluate the time to progression in the treated lobe for this patient population.
II. To evaluate the overall survival for this patient population. III. To evaluate patient tolerance and the toxicity profile of treatment with DEBIRI in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic to the liver and for which standard curative measures do not exist
- •Patients must have received prior irinotecan-based treatment for their disease and had documented progression by RECIST criteria; patients must also have received prior fluoropyrimidine and oxaliplatin-based therapy
- •Liver disease must not be amenable to potentially curative surgical resection
- •Patients must have liver-only or liver-predominant disease to be eligible for this study; hepatic disease must be dominant, but patients are allowed to have extrahepatic disease provided it is not judged likely to be life threatening within 3 months
- •Patients must have a patent portal vein as documented by CT, MRI, or ultrasound
- •Prior radiation therapy is allowed but must have been completed >= 4 weeks prior to study entry; patients with history of prior radiation to the liver including radio-labeled microspheres cannot take part in this study
- •Eastern Cooperative Oncology Group performance status 0-1
- •Previous surgery or RFA to the liver is allowed; patients with history of chemoembolization or radio-labeled microspheres are excluded
- •Life expectancy of >= 12 weeks
- •Leukocytes >= 3,000/uL
- •Absolute neutrophil count >= 1,500/uL
- •Platelets >= 100,000/uL
- •Total bilirubin =< ULN
- •AST(SGOT)/ALT(SGPT)/Alkaline Phosphatase =< 2.5 X institutional ULN
- •Creatinine < 2.0 mg/dL
- •PT/PTT < 1.5 X ULN
- •Women of childbearing potential (WOCBP) and sexually active males must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study; WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal; even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) should be considered to be of child bearing potential
- •Patients must demonstrate ability to understand and the willingness to sign a written informed consent document
排除标准
- •Patients who have had chemotherapy (including targeted therapy i.e. cetuximab, panitumumab) or radiotherapy =< 4 weeks or treatment with bevacizumab =< 6 weeks prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than 4 weeks earlier, with the exclusion of alopecia or neuropathy; patient with history of radiation to the liver including radio-labeled microspheres at any point in their past will be excluded
- •Patients may not be receiving nor have received any other investigational agent =< 4 weeks prior to study registration
- •Pregnant or nursing women may not participate in this trial because of the increased risk of fetal harm including death from the therapeutic agents
- •Patients with known brain metastases are excluded from this study because of their poor prognosis and frequent development of progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events
- •As patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, known HIV-positive patients and those with known hepatitis B or C are excluded from the study
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active bacterial infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Patients with clinically evident ascites requiring medical management or paracentesis, or Childs-Pugh score B/C are not eligible
- •Patients with evidence of other cancer within 5 years, excluding adequately treated basal cell carcinoma of the skin
- •Patient with significant cardiac, renal or hematologic or pulmonary dysfunction
- •Patients with previous chemoembolization to liver metastases
- •Patients may not receive any other anticancer therapy while on study, including immunotherapy; patients may not receive any other clinical investigational drug
结局指标
主要结局
Time to Progression
时间窗: Duration of time from start of treatment to progression
Patient Tolerance and Toxicity Profile
时间窗: First treatment then 30 days after completion of treatment then every 3 months for 2 years
Overall Survival
时间窗: 30 days after completion of treatment then every 3 months for 2 years
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing ChemotherapyColorectal CancerNCT01079780Eastern Cooperative Oncology Group136
已完成
2 期
Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast CancerBreast CancerNCT00693719University of Arizona31
已完成
2 期
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or SarcomaSarcomaNCT00003955Children's Oncology Group77
已完成
2 期
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With ChemotherapyTransitional Cell Cancer of the Renal Pelvis and UreterUrethral CancerBladder CancerNCT00066612SWOG Cancer Research Network45
已完成
2 期
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung CancerLung CancerNCT00387660University of California, Davis80